RVL Pharmaceuticals plc Notes Payable, Fair Value Disclosure
RVL Pharmaceuticals plc had Notes Payable, Fair Value Disclosure of $75.00 million as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2022-11-10
- 2022-09-30: Notes Payable, Fair Value Disclosure $75.00M.
- 2022-06-30: Notes Payable, Fair Value Disclosure $55.00M.
- 2022-03-31: Notes Payable, Fair Value Disclosure $55.00M.
- 2021-12-31: Notes Payable, Fair Value Disclosure $55.00M; Notes Payable, Fair Value Disclosure as first filed $43.80M.
| Period end | Notes Payable, Fair Value Disclosure | Notes Payable, Fair Value Disclosure as first filed |
|---|---|---|
| 2022-09-30 | $75.00M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $55.00M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $55.00M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $55.00M 10-Q · filed 2022-11-10 | $43.80M 10-K · filed 2022-03-30 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-30 |